Search Results
Your search for The ASCO Post matches 17144 pages
Showing 7351 - 7400Winship Cancer Institute Awarded Lung Cancer SPORE Grant From NCI
The Winship Cancer Institute of Emory University has been awarded a 5-year, $9.7 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to study new approaches for lung cancer treatment. It is reportedly the only grant of its kind to be awarded in...
Family History of Melanoma May Increase Risk for Nonmelanoma Skin Cancers
A study by Wei et al in the Journal of the American Academy of Dermatology has found that individuals with a first-degree relative with a history of melanoma are at an increased risk for melanomas and keratinocyte cancers such as squamous cell carcinoma and basal cell carcinoma. Methods...
Timing of Postoperative Treatment After Diagnosis of Breast Cancer and Survival
When chemotherapy is recommended as part of a treatment plan, women with breast cancer should start postoperative treatment ideally within 4 months of their cancer diagnosis. New study findings published by Kupstas et al in the Annals of Surgical Oncology show delaying chemotherapy further is...
FDA Grants Breakthrough Therapy Designation to Pembrolizumab Plus Lenvatinib in Advanced HCC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the programmed cell death protein 1 inhibitor pembrolizumab in combination with the multiple kinase inhibitor lenvatinib for the potential first-line treatment of patients with advanced unresectable...
Study Looks at Effect of Parenthood, Gender on Conference Attendance and Early Career Satisfaction
For oncologists in the beginning of their careers, scientific conferences present an opportunity to network, share research, gain new knowledge, and advance in their career. However, many women find themselves skipping these conferences because of family obligations, a new research letter published ...
Rates of Colorectal Cancer Diagnosis in Adults Younger Than Age 50
A new study published by Virostko et al in Cancer found that the proportion of adults diagnosed with colorectal cancer under age 50 in the United States has continued to increase over the past decade, and younger adults are diagnosed with more advanced disease. To determine recent trends in...
Metabolic Changes May Signal Development of Chemotherapy-Associated Cardiotoxicity
To learn more about the processes that lead to chemotherapy-associated cardiotoxicity, a team of researchers at Beth Israel Deaconess Medical Center (BIDMC) conducted a study to investigate whether early changes in energy-related metabolites in the blood—measured shortly after...
Artificial Intelligence to Guide Management of Pancreatic Cysts
In a proof-of-concept study, an international scientific team has shown that a laboratory test using artificial intelligence tools has the potential to more accurately sort out which people with pancreatic cysts will eventually develop pancreatic cancers. Their findings were published by Springer...
Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients
In a report published by Jayadevappa et al in JAMA Network Open, researchers found that among older patients with prostate cancer, treatment with androgen-deprivation therapy (ADT) was associated with a subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10...
Stratification Tool to Predict VTE in Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
New research published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network has identified a way to help clinicians caring for patients with multiple myeloma to predict blood clots in order to take preventive action. The researchers established a set of risk factors to...
Upgrading of Nonmelanoma Skin Cancers at the Time of Mohs Surgery
Nonmelanoma skin cancers may display an aggressive histologic subtype that is not diagnosed on initial biopsy. In a prospective, cross-sectional study reported by Kyllo et al in the Journal of the American Academy of Dermatology, researchers determined that a significant portion of nomelanoma...
Poorer Outcomes for Patients With Lung Cancer Undergoing Radiotherapy During Disaster-Level Hurricanes
Patients who experienced a disaster-level hurricance during radiotherapy for lung cancer had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival. These findings come from a...
Does the Association Between Diet and Colonic Mucosa–Associated Microbiota Affect Cancer Risk?
A report published by Liu et al in The American Journal of Clinical Nutrition found an association between diet quality and microbiome composition in human colonic mucosa. The researchers found that a high-quality diet is linked to more potentially beneficial bacteria, whereas a...
Role of IL-6/JAK1 Pathway in the Treatment of Hepatocellular Carcinoma
A recent study published by Chan et al in the Journal of Clinical Investigation found a cellular pathway associated with cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma. IL-6/JAK1 Pathway Researchers...
Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends
A new study finds that trends in colonoscopy rates did not fully align with recent increases in colorectal cancer incidence in younger adults. The findings were published by Fedewa et al in the Journal of Medical Screening. Colorectal cancer incidence rates are declining in adults older than...
Biliary Microbiome Altered in Patients Undergoing Surgery After Neoadjuvant Therapy for Pancreatic Cancer
The biliary microbiome was altered in patients who received neoadjuvant therapy prior to undergoing surgery for pancreatic cancer, according to a study published by Goel et al in HPB. Additionally, more bacteria in patients who underwent surgery after neoadjuvant therapy were resistant to...
Role of Regulatory T Cells in Predicting Breast Cancer Relapse
Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...
Biden Cancer Initiative Suspends All Operations
Today, the Biden Cancer Initiative announced it would suspend all operations. The Initiative, which launched on June 26, 2017, is an independent nonprofit organization that was built on the goals of the White House Cancer Moonshot program created by President Barack Obama and led by Vice President ...
Ivosidenib for Advanced IDH1-Mutated Advanced Cholangiocarcinoma
Ivosidenib, a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), is currently being studied in a phase I clinical trial assessing its efficacy in patients with IDH1-mutated solid tumors. In a report published by Lowery et al in The Lancet Gastroenterology & Hepatology, researchers...
Economic Burden of Cancer in the United States in 2015
There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer is the second-leading cause of death...
Subtypes of Pancreatic Neuroendocrine Tumors and Effect on Disease Recurrence
Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors (pNETs) associated with different risks of recurrence following surgical treatment. The finding could yield predictive tests while focusing vigilant follow-up monitoring on patients with pNETs that have a higher...
Is There an Increased Long-Term Risk for Ovarian Cancer After Assisted Reproductive Technology?
Fertility treatment is not associated with an increased long-term risk of ovarian cancer, according to the results of a large-scale multicenter study presented by Spaan et al at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (Abstract O-183). The findings,...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
Study Identifies Key Biologic Features of Upper Tract Urothelial Carcinoma
A new study published by Robinson et al in Nature Communications aimed to learn more about the biologic characteristics of upper tract urothelial carcinoma to help develop more targeted therapies. “We discovered the defining biologic characteristics of [upper tract urothelial tumors] that...
Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative
Friends of Cancer Research (Friends) is launching the next phase of its Real-World Evidence (RWE) pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in...
Cost-Effectiveness of Single-Marker Genetic Testing vs Multigene Panel Sequencing in Advanced NSCLC
The results of an economic modeling study to estimate the cost-effectiveness of multigene panel sequencing as compared to standard-of-care single-gene tests for patients with advanced non–small cell lung cancer (NSCLC) showed that multigene panel sequencing tests are moderately...
KIR-HLA System Gene Loci Imbalance and Biliary Tract Cancer
Patients with biliary tract cancer have an altered genetic architecture in some immune system receptor systems, according to research published by Cornillet et al in Gastroenterology. Research Findings Researchers at Karolinska Institutet investigated the genetic architecture of two large genetic ...
A Pioneering Surgeon Who Opened Doors for Others, LaSalle D. Leffall, Jr, MD, Dies at 89
Lifting himself from the barriers of the segregated South, LaSalle D. Leffall, Jr, MD, would become a nationally regarded oncologic surgeon who opened doors for other in the medical profession. His career was distinguished by “firsts,” such as the first African America President of both the...
How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy
Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...
FDA Approves New Trastuzumab Biosimilar
On June 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
Endowment Helps George Washington University Cancer Center to Create Position of Dr. Cyrus Katzen Family Director
The George Washington University (GW) Cancer Center has announced the establishment of the Dr. Cyrus Katzen Family Director of the GW Cancer Center, thanks to a gift from GW alumnus and former Board of Trustee member Jay Katzen, MD. The gift will support the ongoing growth and expansion of the GW ...
Queen Elizabeth II Bestows Honor on V. Craig Jordan, OBE, PhD, DSc, FMedSci
On June 7, 2019, Professor V. Craig Jordan, OBE, PhD, DSc, FMedSci, was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II on her 93rd birthday. Each year, the Queen recognizes the achievements of people from across the British Commonwealth. Dr. ...
Willie Underwood III, MD, MSc, MPH, Elected to AMA Board of Trustees
The American Medical Association (AMA) announced the election of Willie Underwood III, MD, MSc, MPH, a urologist based in Buffalo, New York, to its Board of Trustees. A board-certified urologic surgeon specializing in prostate cancer, Dr. Underwood has been an active leader in organized medicine...
Erratum
In the June 10, 2019, issue of The ASCO Post, a photo on page 69, in an article about the National Comprehensive Cancer Network Board of Directors, was incorrectly identified as Ronald Walters, MD, of The University of Texas MD Anderson Cancer Center. The photo was actually of Roland B. Walter,...
Joann Sweasy, PhD, Joins University of Arizona Cancer Center as Associate Director for Basic Sciences
Joann Sweasy, PhD, an expert in DNA repair and genomic instability, has joined the University of Arizona Cancer Center as Associate Director for Basic Sciences. Dr. Sweasy also has been appointed to a joint faculty position at the University of Arizona College of Medicine, Tucson, in the...
FDA Approves First-Line Ivosidenib for IDH1-Mutated AML
On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...
Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?
Findings from a study of patients who received radioactive iodine treatment for hyperthyroidism show a modest association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers at the National Cancer Institute (NCI), was...
Risk-Prediction Model Aims to Predict Incident Lung Cancer in Patients With a Pulmonary Nodule
A risk-prediction model developed using clinical and radiologic features could stratify individuals presenting with a lung nodule as having a high or low risk for lung cancer, according to a study published by Nemesure et al in Cancer Prevention Research. “While lung nodules are not...
Benefit Seen With Targeted Therapies in Elderly and Medically Complex Patients With Metastatic RCC
Many elderly and medically complex patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials—saw overall survival benefits from treatment with targeted therapies, according to a study that analyzed 13 years of data on Medicare patients...
ESMO World GI 2019: BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the phase III BEACON CRC clinical trial. These findings were presented by Kopetz et al at the European...
ESMO World GI 2019: REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer
Regorafenib is often administered to patients with refractory metastatic colorectal cancer. However, some of the adverse events related to the use of this drug often limit its use in clinical practice. A study reported by Argilés et al at the European Society for Medical Oncology (ESMO)...
ESMO World GI 2019: Incidence of Gastric Cancer in Younger Individuals
The incidence of gastric cancer has been increasing in younger individuals, and those under 40 with chronic digestive symptoms should be more actively investigated. These findings follow new data from a retrospective, observational study in Mexico, which showed that 1 in 7 of over 2,000...
FDA Grants Accelerated Approval to Selinexor in Combination With Dexamethasone in Pentarefractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two...
Combination Immunotherapy and Inhibitors of DNA Damage Repair in the Treatment of Small Cell Lung Cancer
Unlike non–small cell lung cancer (NSCLC), which has seen a paradigm shift in treatment modalities with the discovery of genetic signatures (including EGFR mutations) that are responsive to targeted drugs, systemic treatment of small cell lung cancer (SCLC) has remained largely unchanged for over...
SOPHIA Trial Tests Margetuximab in Heavily Pretreated Patients With HER2-Positive Metastatic Breast Cancer
In the phase III SOPHIA trial of 536 heavily pretreated patients with HER2-positive metastatic breast cancer, the novel anti-HER2 antibody margetuximab plus chemotherapy led to significant improvements in progression-free survival, response, and clinical benefit compared with...
Do Statins Lower the Risk of Cardiovascular Complications in Patients Treated With Radiotherapy to the Chest, Neck, or Head?
Patients with cancer who took cholesterol-lowering statin medication following radiation therapy of the chest, neck, or head had significantly reduced risk of suffering a stroke—and possibly other cardiovascular complications—according to research published by Boulet et al in...
SNMMI 2019: Phase I/II Trial of Lutetium-177–PSMA-617 Plus Idronoxil in Metastatic Castration-Resistant Prostate Cancer
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects, according to research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and published by Emmett et al in The Journal ...
SNMMI 2019: Vest to Personalize Lu-177 Dotatate Therapy for Neuroendocrine Tumors
Researchers at the University of Washington are developing a user-friendly vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin receptor 2–positive neuroendocrine tumors (NETs). Their study was presented at the 2019 Annual Meeting...
Expert Point of View: Eric P. Winer, MD, FASCO, and Sandra M. Swain, MD, FACP, FASCO
Eric P. Winer, MD, FASCO, Thompson Chair in Breast Cancer Research and Professor of Medicine, Harvard Medical School, and Director of the Breast Cancer Program at Dana-Farber Cancer Institute, Boston, commented on Dr. Sparano’s presentation for The ASCO Post. “We already use information in...
Winning the Lottery
I was born at the beginning of World War II in a country half way around the world from the fighting. As a child, I was immune to the carnage. My father was too old to be included, although his elder brother had been killed in World War I. Thousands of families in many countries lost a father, a...
